Furthermore, Belumosudil’s original indication as a ROCK2 inhibitor and Elraglusib’s role as a GSK-3β inhibitor are acknowledged, underscoring that their repurposing for AML entails known off-target activities [23,25]. Here, ROCK2 is linked to acute myeloid leukemia.